STAT
APRIL 29, 2025
The explosion of compounded GLP-1 offerings over the past two years is coming to an end, and many patients are left with no good options. Blockbuster obesity and diabetes drugs — such as Wegovy, Ozempic, and Mounjaro — are no longer deemed by regulators to be in shortage, so compounding pharmacies and the telehealth companies they work with must stop offering copies of the treatments.
PharmaVoice
APRIL 29, 2025
U.S. health agencies are taking the fight to vaccine and mRNA research, which could have lasting repercussions on medical and scientific advancements.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
APRIL 29, 2025
The word came down at 9 a.m. Pacific on April 14 that they were done. Marcia Stefanick of Stanford and three other leaders of regional centers that for decades have researched women’s health heard from their study’s national leaders that their funding would end with the fiscal year. They all had contracts ready and waiting to be signed to extend their parts of the Women’s Health Initiative, a massive, groundbreaking study that has changed medical practice on hormone therapy,
Express Pharma
APRIL 29, 2025
he Authentication Solution Providers Association (ASPA) conducted its MEA Open House on April 24 2025 at Anantara Downtown Dubai. The event brought together 46 delegates representing 17 companies from the authentication, packaging, and brand protection industries. The initiative was part of ASPAs strategy to expand its presence and strengthen collaborative efforts to combat counterfeiting in the Middle East and Africa (MEA) region.
Speaker: Jennifer Hill
Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.
STAT
APRIL 29, 2025
After 15 years, the Affordable Care Act (ACA) has survived its share of challenges at the Supreme Court. On April 21, I attended the court’s first hearing in the latest of the series of ACA challenges, Kennedy v. Braidwood, which is focused on the ACA’s preventive services coverage requirement. I proudly represented 20 HIV advocacy organizations as amici in the case , urging the court to uphold the law, which requires payer coverage of items and
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
STAT
APRIL 29, 2025
File this under “So close, yet so far.” After several years of struggling with regulatory hurdles to win approval for its rare disease drug, Stealth BioTherapeutics had expected the U.S. Food and Drug Administration to respond on Tuesday to its marketing application. But late last week, the company received a letter saying there was a delay.
Pharma Marketing Network
APRIL 29, 2025
Introduction Is traditional advertising losing its edge in the pharmaceutical world? As the industry shifts toward data-driven strategies, the power of audience targeting continues to redefine how brands connect with healthcare professionals (HCPs) and patients. While print ads, radio spots, and mass media campaigns once dominated, the ability to reach the right person at the right time through digital channels has quickly taken the lead.
STAT
APRIL 29, 2025
Gilead Sciences agreed to pay $202 million to settle allegations of paying kickbacks to doctors in exchange for prescribing several of its HIV medicines, the latest example of a controversial practice that has come back to haunt numerous drugmakers over the years. From 2011 through 2017, Gilead held more than 17,300 speaker programs of which 9,500 were dinners to promote sales of HIV drugs that were supposed to be educational.
Pharmafile
APRIL 29, 2025
The EU has granted marketing authorisation (MA) for Filspari CSL Vifor and Travere Therapeutics therapy for primary IgA nephropathy (IgAN), a rare kidney disease advancing the ability to administer the therapy to patients globally. Filspari is a dual endothelin angiotensin receptor antagonist(DEARA), a non-immunosuppressive therapy for the treatment of IgAN.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
STAT
APRIL 29, 2025
Novo Nordisk is expanding its efforts to sell its obesity drug Wegovy directly to patients, striking agreements with telehealth companies including Hims & Hers, Ro, and LifeMD. Novo last month launched a new direct-to-consumer website called NovoCare Pharmacy that sells Wegovy, which normally carries a list price of about $1,350 a month, at $499 a month to patients who are paying on their own without insurance.
Pharma Marketing Network
APRIL 29, 2025
Introduction When was the last time a glossy pharma ad truly resonated with a patient living with chronic illness? In today’s healthcare marketing landscape, trust is the new currencyand real stories matter more than polished commercials. Thats why Influencer Marketing In Pharma is gaining momentum as a critical tool for reaching audiences in a more authentic, impactful way.
STAT
APRIL 29, 2025
BridgeBio’s recently approved heart drug brought in $36.7 million in sales in the first quarter, blowing past expectations as the biotech continues to see a strong demand for its first major commercial product. Analysts had estimated that the treatment, called Attruby, would bring in sales of $12 million, but Wall Street’s “whisper number” was $17 million to $20 million.
European Pharmaceutical Review
APRIL 29, 2025
The US Pharmacopeia (USP) has launched a selection of resources, including reference materials and standards, to support developers and manufacturers of AAV-based gene therapies. Alongside these resources, USP is publishing the proposed General Chapter <1067> AAV Best Practices for the Manufacture and Quality Control of Recombinant Adeno-Associated Virus (rAAV) Gene Therapy Products.
Advertisement
Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.
STAT
APRIL 29, 2025
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, we’ve got a bunch of news this morning about GLP-1 drugs, compounding, and biotechs’ interactions with the FDA. Let’s get into it.
Pharmafile
APRIL 29, 2025
Gifthealth, a technology-driven pharmacy care company, has appointed Chip Parkinson as its new chief executive officer. The move marks a strategic step in accelerating the companys mission to improve prescription efficiency and accessibility through its digital platform. Parkinson brings over three decades of leadership experience across biotech, pharmacy benefit management, diagnostics and pharma industries.
STAT
APRIL 29, 2025
Y ou’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday. As of last week, Chris Klomp is in charge of the Center for Medicare. Unlike predecessors, he’s not a policy wonk.
The Pharmacist
APRIL 29, 2025
Police made 12 arrests this morning as part of a major investigation into organised trafficking of unlicensed medicines. The Medicines and Healthcare products Regulatory Agency (MHRA) said the operation nicknamed Operation Subaru was 'the largest criminal investigation into organised medicines trafficking' in the organisation's 22-year history. 'The individuals have been arrested on suspicion […] The post Trafficked medicines seized in 'largest-ever' MHRA crackdown appeared fir
Speaker: Joe Sharpe and James Carlson
Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.
STAT
APRIL 29, 2025
Top of the morning to you. And a fine one it is. Lots of sunshine and clear blue skies are once again enveloping the Pharmalot campus, where the official mascots are bounding about the grounds in search of creatures to terrorize. As for us, we are as busy as ever hunting and gathering items of interest. We trust you have your own hectic agendas. So join us as we hoist the ever-present cup of stimulation — our choice today is roasted coconut — and attack the fast-growing to-do list.
Pharmafile
APRIL 29, 2025
Global R&D sample stability and biorepository storage company, Astoriom, has announced the appointment of Ryan Smith as global head of sales, supporting the companys ambition to continue advancing internationally. Having led global commercial teams in life sciences for over two decades, Smith has thorough experience in delivering revenue growth, improving commercial processes and scaling global […] The post Ryan Smith appointed as global head of sales at Astoriom appeared first on Phar
STAT
APRIL 29, 2025
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning. Liz Cooney here taking a turn with the newsletter while Theresa’s out exploring the world.
Drug Patent Watch
APRIL 29, 2025
"Patent Infringement Alert: Are You Sitting on a Goldmine? Did you know that over 40% of pharmaceutical patents in the US are considered "weak" due to flawed patent applications or inadequate patent prosecution? At DrugPatentWatch, we've identified a staggering number of opportunities for generic manufacturers to invalidate these weak patents and bring affordable medications to market.
Advertisement
Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.
Board Vitals - Pharmacist
APRIL 29, 2025
Getting ready for your board exam is a big step in your professional career. While the pressure to do well can be intense, having the right strategy and study resources is key. Following a six-month study plan will help you cover all the essential material while you build your confidence for exam day. Why Should You Study for 6 Months? Between work and other responsibilities, you likely have enough to do without worrying about preparing for your board exams.
Pharma and Life Sciences Blog
APRIL 29, 2025
Global Chemicals Storage Company Reduces Supply Risks and Costs With GEPs Help priyanka.katke Tue, 04/29/2025 - 18:11 A chemicals storage company found itself in a precarious position amid escalating global tensions: Shipping delays and cost overruns were threatening to upend its expansion project. Procurement executives, engineers, and project managers were all busy with firefighting, leaving little room for strategic work.
Safe Biologics
APRIL 29, 2025
April 29, 2025 The Alliance for Safe Biologic Medicines (ASBM) commends Senator Bill Cassidy and the Senate HELP Committee for their new report , “Congress Must Act to Bring Needed Reforms to the 340B Program.” The program is designed to support underserved populations by ensuring access to medicines by allowing qualifying entities to safety-net hospitals, community health centers, and federally qualified health centers (FQHCs) to purchase outpatient drugs at discounted prices and re
Pharma and Life Sciences Blog
APRIL 29, 2025
Utility Services Company Streamlines Source-to-Pay, Boosts Savings and Efficiency With GEPs Help Pranil Tue, 04/29/2025 - 17:17 Mergers are rarely seamless, as we all know. After a merger, a leading utility solutions company was grappling with siloed procurement operations, inconsistent spend classifications and no clear plan to find and capture synergies.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharmaceutical Technology
APRIL 29, 2025
The EC has granted conditional marketing approval to Regeneron Pharmaceuticals bispecific antibody Lynozyfic for treating multiple myeloma.
Drug Patent Watch
APRIL 29, 2025
"Market Access: The Hidden Hurdle in Generic Drug Commercialization As a seasoned pharmaceutical professional, I've seen it time and time again: a generic drug finally receives FDA approval, only to stall in the market due to a seemingly insurmountable obstacle - market access. But what exactly is market access, and why does it hold such sway over the commercialization of generic drugs?
Pharmaceutical Technology
APRIL 29, 2025
Prilenia has signed a partnership and licence agreement with Ferrer for jointly developing and commercialising pridopidine in Europe.
Expert insights. Personalized for you.
264 
Let's personalize your content